Stemline Therapeutics Inc (NASDAQ:STML) insider David Gionco sold 4,250 shares of Stemline Therapeutics stock in a transaction dated Wednesday, January 17th. The stock was sold at an average price of $13.43, for a total value of $57,077.50. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Shares of Stemline Therapeutics Inc (NASDAQ:STML) traded up $0.15 on Friday, reaching $13.55. 110,081 shares of the company’s stock were exchanged, compared to its average volume of 180,192. The company has a market capitalization of $340.11, a PE ratio of -5.27 and a beta of -0.02. Stemline Therapeutics Inc has a 1 year low of $5.50 and a 1 year high of $16.20.

Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.11). Stemline Therapeutics had a negative return on equity of 75.50% and a negative net margin of 4,689.63%. research analysts predict that Stemline Therapeutics Inc will post -2.71 earnings per share for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in STML. Rhumbline Advisers lifted its stake in Stemline Therapeutics by 18.5% during the second quarter. Rhumbline Advisers now owns 27,358 shares of the biopharmaceutical company’s stock worth $252,000 after purchasing an additional 4,280 shares during the period. Alliancebernstein L.P. bought a new position in Stemline Therapeutics during the second quarter worth about $178,000. Teachers Advisors LLC lifted its stake in Stemline Therapeutics by 1.3% during the second quarter. Teachers Advisors LLC now owns 43,397 shares of the biopharmaceutical company’s stock worth $399,000 after purchasing an additional 541 shares during the period. Nationwide Fund Advisors lifted its stake in Stemline Therapeutics by 7.2% during the second quarter. Nationwide Fund Advisors now owns 12,755 shares of the biopharmaceutical company’s stock worth $117,000 after purchasing an additional 855 shares during the period. Finally, Northern Trust Corp lifted its stake in Stemline Therapeutics by 18.0% during the second quarter. Northern Trust Corp now owns 274,824 shares of the biopharmaceutical company’s stock worth $2,529,000 after purchasing an additional 41,898 shares during the period. Hedge funds and other institutional investors own 50.24% of the company’s stock.

A number of equities research analysts recently weighed in on the company. Zacks Investment Research raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, January 5th. ValuEngine raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. BidaskClub raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. HC Wainwright set a $38.00 target price on Stemline Therapeutics and gave the stock a “buy” rating in a research report on Thursday, December 14th. Finally, Cowen restated a “buy” rating on shares of Stemline Therapeutics in a research note on Tuesday, October 31st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $33.75.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Stemline Therapeutics Inc (STML) Insider Sells 4,250 Shares of Stock” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.watchlistnews.com/insider-selling-stemline-therapeutics-inc-stml-insider-sells-4250-shares-of-stock/1814673.html.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Insider Buying and Selling by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.